P/B
2,3
Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
$2.1B
Market Cap • 9/28/2026
1990
(36 years)
Founded
1994
(32 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
37,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
37,2
EPS
—
Market Cap
Market Cap
2,1B
EV
1,5B
EV/Revenue
26,7
EV/EBITDA
-10,4
EV/EBIT
-10,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-52,2%
Total Yield
-52,2%
Payout
0%
Retained Earnings
-3,8B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
241,4%
Capex/Revenue
0,4%
Capex/D&A
35,2%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-12,3%
CAGR Op. Income 5Y
-20,1%
CAGR Net Income 5Y
-20,2%
CAGR EPS 5Y
-29,9%
CAGR OCF 5Y
-5,6%
Leverage
N.D./EBITDA
4,3
Debt/Equity
0%
Current Ratio
10,4
Quick Ratio
9,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!